Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
143 participants
INTERVENTIONAL
2016-11-15
2018-11-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism
NCT02730169
Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men
NCT01200862
Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism
NCT02159469
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
NCT01446042
Study to Test Safety, Tolerability and Blood Levels of GSK971086 After 1 Dose & 7 Days of Dosing in Healthy Adult Males
NCT00540553
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BGS649 0.1 mg
Drug: BGS649 Dose 1 weekly
BGS649
Capsules will be taken weekly for a maximum of 24 weeks
BGS649 0.3 mg
Drug: BGS649 Dose 2 weekly
BGS649
Capsules will be taken weekly for a maximum of 24 weeks
BGS649 1.0 mg
Drug: BGS649 Dose 3 weekly
BGS649
Capsules will be taken weekly for a maximum of 24 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BGS649
Capsules will be taken weekly for a maximum of 24 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* In opinion of the investigator has been compliant with the requirements of the Study MBGS205 protocol.
Exclusion Criteria
18 Years
65 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mereo BioPharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hugh Jones
Role: PRINCIPAL_INVESTIGATOR
Barnsley Hospital NHS Foundation Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mereo Research Site
Mobile, Alabama, United States
Mereo Research Site
Chandler, Arizona, United States
Mereo Research Site
Phoenix, Arizona, United States
Mereo Research Site
Scottsdale, Arizona, United States
Mereo Research Site
Anaheim, California, United States
Mereo Research Site
Greenbrae, California, United States
Mereo Research Site
Lincoln, California, United States
Mereo Research Site
Los Angeles, California, United States
Mereo Research Site
San Diego, California, United States
Mereo Research Site
Bradenton, Florida, United States
Mereo Research Site
DeLand, Florida, United States
Mereo Research Site
Fort Myers, Florida, United States
Mereo Research Site
Hialeah, Florida, United States
Mereo Research Site
St. Petersburg, Florida, United States
Mereo Research Site
Meridian, Idaho, United States
Mereo Research Site
Evansville, Indiana, United States
Mereo Research Site
Marrero, Louisiana, United States
Mereo Research Site
Elkridge, Maryland, United States
Mereo Research Site
Henderson, Nevada, United States
Mereo Research Site
Las Vegas, Nevada, United States
Mereo Research Site
Albany, New York, United States
Mereo Research Site
Garden City, New York, United States
Mereo Research Site
Great Neck, New York, United States
Mereo Research Site
New York, New York, United States
Mereo Research Site
Rochester, New York, United States
Mereo Research Site
Charlotte, North Carolina, United States
Mereo Research Site
Raleigh, North Carolina, United States
Mereo Research Site
Winston-Salem, North Carolina, United States
Mereo Research Site
Mt. Pleasant, South Carolina, United States
Mereo Research Site
Nashville, Tennessee, United States
Mereo Research Site
Dallas, Texas, United States
Mereo Research Site
Fort Worth, Texas, United States
Mereo Research Site
Pearland, Texas, United States
Mereo Research Site
San Antonio, Texas, United States
Mereo Research Site
West Jordan, Utah, United States
Mereo Research Site
Norfolk, Virginia, United States
Mereo Research Site
Kenosha, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MBGS206
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.